Phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers
An open-label, randomized, single-dose, 2-sequence, 4-period, cross-over, phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
47
H plus Yangji hospital
Seoul, South Korea
Cmax of CKD-331
Cmax: Maximum plasma concentration of the drug
Time frame: Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 34 hours
AUCt of CKD-331
AUCt: Area under the concentration-time curve from time zero to time
Time frame: Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 34 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.